Mesalamine 250 mg Slow Release Capsules are a specialized compounded formulation designed to treat various inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. This prescription medication is formulated with Methocel E4M, a type of controlled-release polymer. This innovative design allows for the gradual release of the encapsulated mesalamine over an extended period, providing sustained therapeutic effects.

The slow and sustained release of mesalamine from these capsules allows for a more consistent therapeutic effect, reducing the risk of side effects associated with higher doses of the medication. This formulation also offers the advantage of reduced dosing frequency, which can lead to improved patient compliance, particularly for medications requiring a controlled and prolonged release profile.

Mesalamine 250 mg Slow Release Capsules are taken orally, typically once a day. It is crucial to take this medication exactly as prescribed by your healthcare provider. Do not alter the prescribed dose without consulting your doctor. To minimize the risk of stomach upset, it is recommended to take this medication with food or a full glass of water.

This medication works by reducing inflammation in the bowel, thereby improving symptoms associated with ulcerative colitis and Crohn's disease. However, like all medications, Mesalamine 250 mg Slow Release Capsules can cause side effects. Common side effects include nausea, vomiting, diarrhea, and headache. If you experience any of these or other side effects, it is important to contact your healthcare provider immediately.

If you have any questions or concerns about Mesalamine 250 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need.

Mesalamine 250 mg Slow Release Capsules are a specialized formulation designed for the treatment of mild to moderate ulcerative colitis, proctitis, and proctosigmoiditis. This medication is also utilized to prevent the recurrence of ulcerative colitis. The active ingredient, Mesalamine, functions by reducing inflammation in the colon and rectum, providing relief from these conditions.

The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This technology allows for the gradual release of the encapsulated medication over an extended period of time. This sustained release offers prolonged therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.

It is crucial to take Mesalamine 250 mg Slow Release Capsules as prescribed by your healthcare provider. Do not alter the recommended dose, and do not discontinue the medication without consulting your doctor. This medication may interact with other drugs, including antacids, antibiotics, and sulfa drugs. Therefore, it is important to inform your doctor about all medications, vitamins, and herbal supplements you are currently taking.

Mesalamine 250 mg Slow Release Capsules may cause side effects such as nausea, vomiting, stomach pain, headache, and dizziness. If you experience any of these side effects, it is important to contact your healthcare provider immediately.

If you have any questions or concerns about Mesalamine 250 mg Slow Release Capsules, do not hesitate to reach out to your healthcare provider or pharmacist for further information and guidance.

Mesalamine 250 mg Slow Release Capsules are a specialized formulation designed to treat conditions such as ulcerative colitis, proctitis, and proctosigmoiditis. The active ingredient, mesalamine, is an anti-inflammatory drug that targets inflammation in the lining of the colon and rectum. The unique feature of these capsules is the incorporation of Methocel E4M, a controlled-release polymer. This polymer is designed to gradually release the encapsulated medication over an extended period, providing sustained therapeutic effects.

The slow release formulation of Mesalamine 250 mg Capsules allows for a more consistent therapeutic effect, reducing the frequency of dosing and potentially improving patient compliance, particularly for medications requiring a controlled and prolonged release profile. It is recommended that these capsules be taken with food and swallowed whole without crushing, chewing, or breaking them.

Patients should adhere to the prescribed dosage of Mesalamine 250 mg Slow Release Capsules as determined by their healthcare provider. The dosage and duration of treatment are typically based on the severity of the condition being treated. It is crucial to follow the medication regimen as directed and not to discontinue the medication without consulting a healthcare provider.

Common side effects of Mesalamine 250 mg Slow Release Capsules may include nausea, vomiting, headache, and abdominal pain. Patients experiencing severe side effects or those that persist should seek medical attention. Healthcare providers prescribing Mesalamine 250 mg Slow Release Capsules should consider the patient's medical history and concurrent medications. Monitoring the patient's response to the medication and adjusting the dosage as necessary is also important.

If you have any questions or concerns about Mesalamine 250 mg Slow Release Capsules, please consult with your healthcare provider for further information and guidance.

Mesalamine 250 mg Slow Release Capsules are a compounded formulation designed to provide a controlled and prolonged release of the active ingredient, mesalamine. This is achieved through the use of Methocel E4M, a type of controlled-release polymer. The slow release of the medication offers sustained therapeutic effects, which can lead to reduced dosing frequency and improved patient compliance, particularly beneficial for medications requiring a controlled release profile.

This formulation of Mesalamine may be used to treat a variety of inflammatory bowel diseases, including microscopic colitis, pouchitis, and ischemic colitis. It may also be effective in treating mild to moderate flares of ulcerative colitis. However, it is important to note that this formulation is not recommended for use in children under the age of 6 due to the potential for adverse effects.

Furthermore, this formulation should not be used in patients with severe renal impairment or those with a known hypersensitivity to mesalamine or any of its components. To reduce the risk of kidney stones, patients are advised to take this medication with food and to drink plenty of fluids. If any adverse reactions occur, patients should contact their healthcare provider immediately.

For any further questions or concerns regarding the use of Mesalamine 250 mg Slow Release Capsules, please do not hesitate to reach out. It is our priority to ensure the safe and effective use of this medication.